Ganguli M, Burmeister L A, Seaberg E C, Belle S, DeKosky S T
Department of Psychiatry, School of Medicine, University of Pittsburgh, Pennsylvania, USA.
Biol Psychiatry. 1996 Oct 15;40(8):714-25. doi: 10.1016/0006-3223(95)00489-0.
We report on 194 individuals (96 men and 98 women), aged 65 and over, who had dementia assessments and basal TSH measurements as part of an ongoing epidemiological study of dementing disorders in a larger population. Dementia was diagnosed according to DSM-III-R and measured by the Clinical Dementia Rating scale; CDR scores of 0, 0.5, and > or = 1, represent individuals with no dementia (n = 122), possible dementia (n = 29), and definite dementia (n = 43), respectively. The odds ratio for the association of elevated TSH with definite dementia (CDR > or = 1) was 3.8 (95% confidence interval = 1.6, 9.1) and with possible and/or definite dementia (CDR > or = 0.5) was 3.8 (95% confidence interval = 1.6, 9.2), after adjusting for the effects of age, gender, and level of education. This is the first community-based study to report an association between TSH elevation and dementia. Our findings are consistent with recent evidence that subclinical hypothyroidism is associated with cognitive impairment, and that thyroidal state may influence cerebral metabolism.
我们报告了194名年龄在65岁及以上的个体(96名男性和98名女性),他们作为对更大人群中痴呆症进行的一项正在进行的流行病学研究的一部分,接受了痴呆症评估和基础促甲状腺激素(TSH)测量。根据《精神疾病诊断与统计手册》第三版修订版(DSM-III-R)诊断痴呆症,并通过临床痴呆评定量表进行测量;临床痴呆评定量表评分为0、0.5以及≥1分别代表无痴呆症个体(n = 122)、可能患有痴呆症个体(n = 29)和确诊痴呆症个体(n = 43)。在对年龄、性别和教育水平的影响进行校正后,促甲状腺激素升高与确诊痴呆症(临床痴呆评定量表评分≥1)的关联比值比为3.8(95%置信区间 = 1.6, 9.1),与可能患有和/或确诊痴呆症(临床痴呆评定量表评分≥0.5)的关联比值比为3.8(95%置信区间 = 1.6, 9.2)。这是第一项报告促甲状腺激素升高与痴呆症之间存在关联的基于社区的研究。我们的研究结果与最近的证据一致,即亚临床甲状腺功能减退与认知障碍有关,并且甲状腺状态可能影响大脑代谢。